[PRNewswire] Mylan NV (NASDAQ:MYL)(TREND ANALYSIS) commented on the voluntary nationwide recall of Sanofi’s Auvi-Q® (epinephrine injection, USP) auto-injector. Mylan confirms that EpiPen® and EpiPen Jr® (epinephrine injection) Auto-Injectors are not affected by the Auvi-Q® recall, and the company has sufficient supply of EpiPen® Auto-Injector to meet any anticipated demand.
Yesterday, Sanofi announced the recall of all Auvi-Q® auto-injectors currently on the market, including the 0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers. According to Sanofi, Auvi-Q® products have been found to potentially have inaccurate dosage delivery. If a patient experiencing a serious allergic reaction did not receive the intended dose, there could be significant health consequences. Given the life-threatening nature of anaphylaxis, those affected by the recall are encouraged to contact their healthcare provider as soon as possible to obtain a prescription for EpiPen® Auto-Injector. According to Sanofi, any out of pocket costs incurred for a new epinephrine auto-injector will be reimbursed. Additional information related to the Auvi-Q® recall can be found on Auvi-Q.com or by calling 1-866-726-6340 or emailing moc.i1446339304fonas1446339304@sc1446339304.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Mylan NV (NASDAQ:MYL) stock is currently trading 40.31% below its 52-week-high, 21.79% above its 52-week-low. The 1-year stock price history is in the range of $37.59 – $76.69. Mylan NV (MYL) has a price to earnings ratio of 22.15 versus Healthcare sector average of 54.85. MYL stock price has underperformed the Nasdaq by 29.3%. The Generic Drugs company is currently valued at $22.5 billion and its share price closed the last trading session at $45.78. The stock has a 50-day moving average of $44.24 and a 200-day moving average of $60.1.
Mylan NV (MYL) current short interest stands at 62.59 million shares. It has increased by 1% from the same period of last month. Around 17% of the company’s shares, which are float, are short sold. With a 10-days average volume of 10.56 million shares, the number of days required to cover the short positions stand at 6 days.
The company is expected to announce next quarter earnings on October 30, at consensus estimate of $1.38. Mylan NV (MYL) reported last quarter earnings on August 06. The Generic Drugs company announced earnings per share of $0.91 against a consensus Street estimate of $0.87, beating the average estimate by $0.04. This corresponds to an increase of $0.18 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently seventeen analysts that cover Mylan NV stock. Of those seventeen, ten have a Buy rating, seven have a Hold rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $63.
A recent analyst activity consisted of Barclays who initiated their coverage on the stock with Equal-weight rating on September 21. Barclays fixed their price target at $57. This corresponds to a 24.51% upside from the last closing price. On the date of report, the stock closed at $48.16.
Standpoint Research initiated their coverage on the stock with Buy rating on August 26, and fixed their price target at $70. This corresponds to a 52.91% upside from the last closing price. On the date of report, the stock closed at $51.13.
Another research firm was Cowen & Company who downgraded their Outperform rating to Market Perform on July 27. On the date of report, the stock closed at $56.37.
Mylan NV is a global generic and specialty pharmaceuticals company. The Company operates an active pharmaceutical ingredient manufacturer and runs a specialty business focused on respiratory, allergy, and psychiatric therapies.